The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Systemic Juvenile Idiopathic Arthritis

Systemic Juvenile Idiopathic Arthritis

May 9, 2012 • By Rayfel Schneider, MBBCh, and Ronald M. Laxer, MDCM

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Systemic juvenile idiopathic arthritis (sJIA) only accounts for approximately 10% of all types of JIA, but has a disproportionately high morbidity compared with other subtypes. In most children, the disease begins with a severe systemic illness, characterized by fever, rash, and arthralgia or frank arthritis along with other characteristic features that include diffuse lymphadenopathy, hepatosplenomegaly, and serositis, especially pleuritis and pericarditis. Children often require admission to a hospital to facilitate the expeditious investigation of the presenting symptoms, to exclude potential diagnoses such as infections and malignancies, to document the characteristic quotidian fever pattern, and to initiate appropriate treatment. Criteria for the classification of sJIA are shown in Table 1.1 Typical laboratory features include anemia (usually hypochromic and microcytic), leukocytosis (sometimes with prominent leukemoid reactions with white blood cell counts >50,000), thrombocytosis, elevated immunoglobulins, erythrocyte sedimentation rate, and C-reactive protein (CRP), and hypoalbuminemia.

You Might Also Like
  • Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
  • New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
  • Patient Fact Sheet: Juvenile Idiopathic Arthritis
Explore This Issue
May 2012

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE
click for large version
Table 1: Systemic JIA ILAR Classification Criteria1

There is a striking association of sJIA with secondary hemophagocytic lymphohistiocytosis, also known as macrophage activation syndrome (MAS). Although approximately 10% of sJIA patients develop overt MAS, up to 30% of children have evidence of subclinical MAS, characterized by a number of biochemical and immunological markers of MAS, including elevated levels of soluble CD163.2 In fact, some markers of MAS such as elevations of serum ferritin and d-dimers are considered typical laboratory manifestations of active systemic disease. It is interesting to note that both active sJIA and MAS are characterized by natural killer (NK) cell dysfunction. Full-blown MAS complicating sJIA is associated with significant morbidity and potentially mortality.

The following case represents a typical patient with early sJIA. We will present the case and discuss the treatment choices and outcome.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

A child with systemic juvenile idiopathic arthritis and macrophage activation syndrome was found to have this pathognomonic hemophagocytic macrophage (center) in the peripheral blood. The macrophage has engulfed neutrophils, nucleated red cells, and cellular debris.

The Case

A 14-year-old boy was seen in the rheumatology clinic, having been unwell for approximately two months. He initially presented with diffuse arthralgias but subsequently developed fevers up to 102°F, usually once daily in the evening or early morning. He missed several days of school each week and estimated that he had lost 4 to 5 kg in weight. On physical examination, he had a typical systemic rash, diffuse lymphadenopathy, and oligoarthritis involving both wrists and one elbow. He did not have evidence of serositis or hepatosplenomegaly. After investigations excluded infections, malignancies, and other rheumatic diseases, a diagnosis of sJIA was made and he was treated with naproxen 500 mg bid. There was no improvement in his symptoms or laboratory markers when he was seen for a follow-up visit (see Table 2). Once the patient failed this initial nonsteroidal antiinflammatory drug (NSAID) trial, a decision had to be made about the next step in treatment.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Conditions, Guidelines, Rheumatoid Arthritis Tagged With: AC&R, American College of Rheumatology, antiinflammatory, drug, JIA, Juvenile idiopathic arthritis, macrophage activation syndrome, Methotrexate, patient care, Pediatrics, rheumatologist, Steroids, tocilizumab, TreatmentIssue: May 2012

You Might Also Like:
  • Molecular Analysis Reveals Potential Treatment Window for Systemic Juvenile Idiopathic Arthritis
  • New Criteria Released for Macrophage Activation Syndrome in Juvenile Idiopathic Arthritis
  • Patient Fact Sheet: Juvenile Idiopathic Arthritis
  • Growing Up Confident with Juvenile Idiopathic Arthritis

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)